A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa

Trial Profile

A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Levodopa/carbidopa; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms FIRST-STEP
  • Sponsors Novartis
  • Most Recent Events

    • 15 Mar 2009 Results published in Movement Disorders.
    • 26 Aug 2008 Results were presented at the 12th Congress of the European Federation of Neurological Societies.
    • 15 Apr 2008 Results were presented at the American Academy of Neurology Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top